Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET

Company Participants

Carlo Tanzi - Head of Investor Relations

Eric Shaff - President & Chief Executive Officer

Lisa von Moltke - Chief Medical Officer

Matthew Henn - Chief Scientific Officer

David Arkowitz - Chief Financial Officer

Teresa Young - Chief Commercial & Strategy Officer

Conference Call Participants

Peyton Bohnsack - Cowen

Ted Tenthoff - Piper Sandler

Mark Breidenbach - Oppenheimer

John Newman - Canaccord

Operator

Good morning. My name is Colby and I will be your conference operator today. At this time, I would like to welcome everyone to the Third Quarter 2022 Seres Therapeutics, Inc. Earnings Conference Call. [Operator Instructions] Thank you.

I will now turn the call over to Dr. Carlo Tanzi, Head of Investor Relations.

Carlo Tanzi

Thank you and good morning. Our press release for the company's third quarter 2022 financial results and business update became available at 7:00 A.M. Eastern time this morning and can be found on the Investors and News section of the company's website.

I'd like to remind you that we'll be making forward-looking statements, including the potential approval and launch of investigational SER-109 in its status first-in-class oral therapeutic. The anticipated indication for SER-109, the potential for microbiome therapeutics to protect against infection, the use of cash to fund operations and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the Risk Factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future but we disclaim any obligation to do so.

On today's call with prepared remarks, I'm joined by Eric Shaff, Seres' President and CEO; David Arkowitz, CFO; Dr. Lisa von Molke, Chief Medical Officer; Dr. Matthew Henn, Chief Scientific Officer; and additional members of our management team will also be available during the Q&A.

With that, I’ll pass the call to Eric.

Eric Shaff

Thank you, Carlo and good morning, everyone. Seres continues to make excellent progress advancing our microbiome therapeutics approach. As an organization, our top priorities are to secure the regulatory approval of SER-109, our lead microbiome therapeutic candidate for recurrent C. difficile infection and drive commercial success. We were very pleased to recently announce that our SER-109 BLA has been accepted for priority review by the FDA and the agency has provided a PDUFA target action date of April 26, 2023.